StemCell Therapy

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Cellect Biotechnology Ltd. (Nasdaq: APOP) announced today positive final results from its clinical trial of ApoGraft in healthy donors. The studys primary objective was to validate the Company's propriety method of stem cell selection by going through the process of production and characterization with ApoGraft, and was conducted on samples obtained in collaboration with two leading medical centers in Israel, The Schneider Children's Medical Center and the Rambam Medical Center.

Cellects technology enables the use of stem cells for regenerative therapies by eliminating mature cells while leaving the stem cells unharmed using a natural process occurring in the human body, apoptosis (programed cell death), which orders cells to commit suicide. Cellects validated scientific platform, and the focus of its 7 families of patents, is that the apoptosis command destroys primarily mature cells, while stem cells remain alive and flourishing. This process allows for natural enrichment of stem cells, thus enabling stem cell-based therapies or transplantation to possess an abundance of quality stem cells with little to no risk of rejection or other complications, such as Graft versus Host Disease (GvHD).

The study included 104 healthy donors of blood stem cells. The samples (collected under approval of Helsinki committees) represented 5% of a graft used for transplantation into patients. The grafts were processed allowing stem cell production for transplantation with Cellects ApoGraft. The use of the ApoGraft resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.

Dr. Yaron Pereg, Cellects Chief Development Officer, commented: These results from processing human stem cells for bone marrow transplantation using ApoGraft clearly demonstrated that Cellects proprietary platform could improve the outcome of stem cell transplantations in patients suffering from hematological malignancies.

More:
Cellect Biotechnology (APOP) Announces Positive Results of Clinical Trial of ApoGraft - StreetInsider.com

This entry was posted on February 22, 2017 at 5:41 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |